•TNR4 is a multidrug therapy (Ivermectin, Azithromycin, Montelukast and ASA) for COVID-19 cases.
•TNR4 increased the likelihood of recovery 3.4 times in ambulatory COVID-19 cases.
•The multidrug therapy TNR4 reduced the risk of hospitalization by 75%.
•The multidrug therapy TNR4 reduced the risk of death by 81%.
The dose used in the RECOVERY trial, arouses concern because it may have been a disease-aggravating factor negating the therapeutic effect.
The suggested treatment protocol ideally begins when someone first tests positive for COVID-19. Patients are started on a daily “nutraceutical bundle” of zinc sulfate (220 mg), Vitamin D (5000 IU), Vitamin C (3000 mg), and a flavonoid called quercetin (500 mg), found in several fruits and vegetables, which reduces viral replication. All are available over the counter.
For those 50 years or older with one or more comorbidities, an intravenous infusion of monoclonal antibodies is suggested. In addition, the patient is immediately started on an array of anti-infective agents, which includes hydroxychloroquine, ivermectin, azithromycin, doxycycline, and favipiravir. Some patients are started on a steroid like prednisone, and some are given an anticoagulant.
